Skip to main content

Table 1 Baseline characteristics of the study cohort

From: Impact of modified short-term fasting and its combination with a fasting supportive diet during chemotherapy on the incidence and severity of chemotherapy-induced toxicities in cancer patients - a controlled cross-over pilot study

  MW ± SD n (%)
RandomisationGroup A7 (23.3)
Group B9 (30.0)
Group C1 (3.3)
Group D13 (43.3)
DemographyAge (years)54 ± 11
Height (m)1.65 ± 0.07
BMI (kg/m2)26.0 ± 4.6
DiagnosisAdjuvant26 (86.7)
Metastatic or local advanced4 (13.3)
Tumour entityBreast Cancer22 (73,33)
Endometrial Cancer2 (6,7)
Ovarian Cancer2 (6.7)
Cervical Cancer4 (13,3)
T-categoriesT110 (33.3)
T214 (46.7)
T33 (10.0)
T43 (10.0)
Nodal statusN020 (66.7)
N18 (26.7)
N21 (3.3)
N31 (3.3)
MetastasisM027 (90.0)
M13 (10.0)
Chemotherapy regimensPaclitaxel/Carboplatin7 (23.3)
Epirubicin/Cyclophosphamid22 (73.3)
Docetaxel/Cyclophosphamid1 (3.3)
TreatmentAdjuvant chemotherapy6 (20)
Neoadjuvant chemotherapy22 (73.3)
Palliative chemotherapy3 (10.0)
Nutritional status (NRS 2002)121 (70.0)
28 (26.7)
31 (3.3)
Energy requirementBasal metabolic rate (kcal)1391 ± 125
Physical Activity Level1.39 ± 0.06
Active metabolic rate (kcal)1933 ± 178
25% of the active metabolic rate (kcal)484 ± 44